This inventor holds 1 USPTO granted patent. Top assignee: Taisho Pharmaceutical Co., Ltd.. Active years: 1980.
Company Filing History:
Years Active: 1980
Title: Kunio Kangouri: Innovator in Amylase Inhibition
Introduction
Kunio Kangouri is a notable inventor based in Kitamoto, Japan. He has made significant contributions to the field of biochemistry, particularly in the development of amylase inhibitors. His work has implications for various industries, including pharmaceuticals and food technology.
Latest Patents
Kangouri holds a patent for "Novel amylase inhibitors." This invention involves the creation of novel oligosaccharide substances, TAI-A and TAI-B, which exhibit strong inhibitory activity against amylase and invertase. The process involves inoculating a seed of the strain of Streptomyces calvus TM-521 into an aqueous nutrient medium, cultivating it with shaking or through a submerged culture method with aeration, and subsequently separating the produced amylase inhibitors TAI-A and TAI-B from the cultured broth. He has 1 patent to his name.
Career Highlights
Kangouri is associated with Taisho Pharmaceutical Co., Ltd., where he continues to innovate and contribute to the field of pharmaceutical sciences. His work is recognized for its potential to enhance the efficacy of various treatments and products.
Collaborations
Some of his notable coworkers include Shinjuro Namiki and Sadafumi Omura. Their collaborative efforts have further advanced the research and development of amylase inhibitors.
Conclusion
Kunio Kangouri's innovative work in the field of amylase inhibition showcases his dedication to advancing biochemistry. His contributions are valuable to both the pharmaceutical industry and scientific research.